Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNAP -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (82)	11/24/1999 7:56:00 AM
From: Mike McFarland	Respond to of 124

On page 12 of the SNAP '98 Annual Y2 is listed as having primary indication for Pain...Status is at the 'Discovery' stage, and there is a footnote While Synpatic is currently conducting this program independently, Synaptic has agreed to reserve the Y2 receptor as a potential target for drugs for the alleviation of pain exclusively for its collaboration with Grunenthal." NPY5, Obesity, Early Preclinical, Novartis.

To: Biotech Jim who wrote (82)	11/24/1999 3:59:00 PM
From: tommysdad	Respond to of 124

<<Do you know what therapeutic indication might be relevant for either a Y2 receptor agonist or antagonist? >> Well, no. That's the problem, isn't it? Since NPY activates so many receptors (6, I believe, though Y6 may not be relevant in man), without a specific agonist or antagonist, it's going to be tough to figure that one out. And I am not aware of a Y2 knockout model. There is evidence that NPY itself has anti-epileptic properties, and the localization of NPY Y2 receptor suggests this activity is mediated through the Y2 receptor, but I don't believe the data are definitive. So SNAP's guess at pain management is as good as any, I suppose. Hopefully, they have data they haven't published. Like a knock-out or a really good Y2 ligand.